Evidence map›Paper›PMID 36910233›Full record

ArticleFrontiers in microbiology2023

"CORE" a new assay for rapid identification of

Gianluca Foglietta, Elena De Carolis, Giordana Mattana, Manuela Onori, Marilena Agosta, Claudia Niccolai, Vincenzo Di Pilato, Gian Maria Rossolini, Maurizio Sanguinetti, Carlo Federico Perno and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gianluca FogliettaMicrobiology Unit and Diagnostic Immunology, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy.
Elena De CarolisMicrobiology Unit, Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Giordana MattanaMicrobiology Unit and Diagnostic Immunology, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy.
Manuela OnoriMicrobiology Unit and Diagnostic Immunology, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy.
Marilena AgostaMicrobiology Unit and Diagnostic Immunology, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy.
Claudia NiccolaiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Vincenzo Di PilatoDepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.
Gian Maria RossoliniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Maurizio SanguinettiMicrobiology Unit, Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Carlo Federico PernoMicrobiology Unit and Diagnostic Immunology, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy.
Paola BernaschiMicrobiology Unit and Diagnostic Immunology, Bambino Gesù Pediatric Hospital, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the global spread of pan resistant organisms, colistin is actually considered as one of the last resort antibiotics against MDR and XDR bacterial infections. The emergence of colistin resistant strains has been observed worldwide in Gram-negative bacteria, such as

Indexed as

colistin resistance detectionKlebsiella pneumoniaeMALDI-TOF MSpositive-ion moderapid assay

Identifiers

PMID36910233
PMCPMC9992832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.